Synthesis of new thioester derivative of aspirin and study its effect on some biochemical parameters in blood serum of rabbits
Article Sidebar
Main Article Content
Abstract
This presented work was included synthesis of new thioester derivatives by reaction of Aspirin (a non-steroidal anti-inflammatory drugs) (NSAIDs) and Captopril as a carrier which is used as an antihypertensive drug and an inhibitor for angiotensin-converting enzyme (ACE). Aspirin was converted into acid chloride of aspirin then reacted with SH group of captopril to afforded of 1-(3-((2-acetoxybenzoyl)thio)-2-methylpropanoyl)pyrrolidine-2-carboxylic acid and characterized by FT-IR and 1HNMR spectroscopy. The effect of synthesized compound was studied on some biochemical parameters in the blood serum of rabbits. Results of this study indicated: significant increase in the level of total fucose, total protein and globulin. Non- significant increase in the level of albumin, creatinine, glutathione and uric acid, significant decrease in level of Triglycerides and non-significant decrease in the level of Cholesterol, and malondialdehyde.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] H. J. Smith and H. J. Williams, Smith and Williams’ introduction to the principles of drug design and action. CRC Press, 2005.
[2] A. G. Cheetham, R. W. Chakroun, W. Ma, and H. Cui, “Self-assembling prodrugs,” Chem. Soc. Rev., vol. 46, no. 21, pp. 6638–6663, 2017.
[3] Z. Gan, D. Huang, J. Jiang, Y. Li, H. Li, and Y. Ke, “Captopril alleviates hypertension-induced renal damage, inflammation, and NF-κB activation,” Brazilian J. Med. Biol. Res., vol. 51, 2018.
[4] N. Chattipakorn, T. Incharoen, N. Kanlop, and S. Chattipakorn, “Heart rate variability in myocardial infarction and heart failure,” Int. J. Cardiol., vol. 120, no. 3, pp. 289–296, 2007.
[5] K.-C. Chang, Y.-I. Peng, Y.-F. Tsai, Y.-Z. Tseng, and H.-I. Chen, “Hypotensive effects of captopril on physical properties of the arterial system in young and adult rats,” Biogerontology, vol. 2, no. 1, pp. 45–54, 2001.
[6] M. Kubota et al., “Renin–angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice,” Biochem. Biophys. Res. Commun., vol. 410, no. 1, pp. 108–113, 2011.
[7] S. Attoub et al., “Captopril as a potential inhibitor of lung tumor growth and metastasis,” Ann. N. Y. Acad. Sci., vol. 1138, no. 1, pp. 65–72, 2008.
[8] J. J. McNeil et al., “Effect of aspirin on cardiovascular events and bleeding in the healthy elderly,” N. Engl. J. Med., vol. 379, no. 16, pp. 1509–1518, 2018.
[9] N. P. Sharma, L. Dong, C. Yuan, K. R. Noon, and W. L. Smith, “Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids,” Mol. Pharmacol., vol. 77, no. 6, pp. 979–986, 2010.
[10] T. Fujiwara, K. Katakura, and H. Ohira, “Rheumatoid arthritis and gastrointestinal tract lesions (NSAID ulcers, amyloidosis),” in Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases, Springer, 2019, pp. 97–121.
[11] M. Crook, Clinical Biochemistry and Metabolic Medicine, 8th ed. CRC Press, 2013.
[12] M. Schneider, E. Al-Shareffi, and R. S. Haltiwanger, “Biological functions of fucose in mammals,” Glycobiology, vol. 27, no. 7, pp. 601–618, 2017.
[13] B. G. Ng and H. H. Freeze, “Perspectives on glycosylation and its congenital disorders,” Trends Genet., vol. 34, no. 6, pp. 466–476, 2018.
[14] D. M. Minich and B. I. Brown, “A review of dietary (phyto) nutrients for glutathione support,” Nutrients, vol. 11, no. 9, p. 2073, 2019.
[15] L. Kennedy, J. K. Sandhu, M.-E. Harper, and M. Cuperlovic-Culf, “Role of glutathione in cancer: From mechanisms to therapies,” Biomolecules, vol. 10, no. 10, p. 1429, 2020.
[16] M. Morales and S. Munné-Bosch, “Malondialdehyde: facts and artifacts,” Plant Physiol., vol. 180, no. 3, pp. 1246–1250, 2019.
[17] K. Kashani, M. H. Rosner, and M. Ostermann, “Creatinine: from physiology to clinical application,” Eur. J. Intern. Med., vol. 72, pp. 9–14, 2020.
[18] G. Ndrepepa, “Uric acid and cardiovascular disease,” Clin. Chim. acta, vol. 484, pp. 150–163, 2018.
[19] U. Laufs, K. G. Parhofer, H. N. Ginsberg, and R. A. Hegele, “Clinical review on triglycerides,” Eur. Heart J., vol. 41, no. 1, pp. 99-109c, 2020.
[20] L.-H. Li, E. P. Dutkiewicz, Y.-C. Huang, H.-B. Zhou, and C.-C. Hsu, “Analytical methods for cholesterol quantification,” J. food drug Anal., vol. 27, no. 2, pp. 375–386, 2019.
[21] S. Lin et al., “Preparation of novel anthraquinone-based aspirin derivatives with anti-cancer activity,” Eur. J. Pharmacol., vol. 900, p. 174020, 2021.
[22] M. J. E. N. H. Kadhum, K. J. Al Hamdani, and A. S. Alawad, “Relationship between antioxidants glutathione and total α-L-fucose as tumor markers in breast cancer patients,” 2009.
[23] O. Y. Al-Zamely, M. S. Al-Nimer, and R. K. Al-Muslih, “Detection the level of peroxynitrite and related antioxidant status in the serum of patients with acute myocardial infraction,” Nation. J. Chem, vol. 4, no. 1, pp. 625–637, 2001.
[24] J. A. Beuge and S. D. Aust, “Estimation of
serum malondialdehyde level,” Methods Enzymol. Hoffee Jones edt. By Hoffee PA Jone ME. Acad. Press. a Subsid. Harcoart Brace Jovanovich Publ. New York, 1978.
[25] F. S. Algburi and D. M. Najim, “Synthesis of one prodrug and study its effect on som biochemical parameters in blood serum,” Kirkuk Univ. journal/scientific Stud., vol. 11, no. 4, pp. 33–55, 2016.
[26] P. R. D. Manchil, E. T. Joy, M. S. Kiran, J. E. Sherubin, M. F. Khan, and B. S. Aravind, “Correlation of serum levo-fucose levels as a biomarker with tumor node metastasis staging in oral cancer patients,” J. Pharm. Bioallied Sci., vol. 8, no. Suppl 1, p. S147, 2016.
[27] M. Sanda, J. Ahn, P. Kozlik, and R. Goldman, “Analysis of site and structure specific core fucosylation in liver cirrhosis using exoglycosidase-assisted data-independent LC-MS/MS,” Sci. Rep., vol. 11, no. 1, pp. 1–11, 2021.
[28] I. A. Ibrahim, F. S. Al-Joudi, R. W. Sulaiman, and B. H. AL-Saffar, “Captopril interferes with some serum biochemical findings,” African J. Biochem. Res., vol. 4, no. 4, pp. 95–98, 2010.
[29] M. Mahmoudabady, N. Kazemi, S. Niazmand, S. A. Rezaee, M. Soukhtanloo, and M. Hosseini, “The effect of angiotensin-converting enzyme inhibition on inflammatory and angiogenic factors in hypercholesterolemia,” Pharmacol. Reports, vol. 67, no. 5, pp. 837–841, 2015.